In Dry Eye, A Variety Of Mechanisms Pursue Established Therapies
Executive Summary
Market Snapshot: Kala's Phase III nanoparticle along with Aldeyra's aldehyde trap drug and Ocugen's brimonidine/steroid combo, both in Phase II, are among the candidates pursuing Restasis and Xiidra.
You may also be interested in...
Kala’s Third Phase III Trial Should Line Up Approval In Dry Eye
Data showing that endpoints were met for both signs and symptoms of dry eye disease should position Kala’s KRI-121 for US approval. The company hopes to differentiate with short-term flare treatment.
Aldeyra One Step Closer To Joint Treatment For Allergic Conjunctivitis, Dry Eye Disease
With Phase III programs on similar timelines, Aldeyra hopes it may be able to file for both indications concurrently for its aldehyde trap candidate reproxalap.
Deal Watch: Xencor Adds New Bispecific Partner In Agreement With Genentech
Genentech will pay $120m up front to co-develop Xencor’s preclinical IL-15 candidate; deal also includes IL-15 R&D. Taiho licenses lung cancer candidate to Cullinan; Celgene and Triphase partner again.
Need a specific report? 1000+ reports available
Buy Reports